FDA announces drug product recall due to lack of sterility assurance
FUSION IV Pharmaceuticals, Inc dba AXIA Pharmaceutical is voluntarily recalling all unused sterile drug products to the user level as they do not adhere to federal guidelines.
List view / Grid view
FUSION IV Pharmaceuticals, Inc dba AXIA Pharmaceutical is voluntarily recalling all unused sterile drug products to the user level as they do not adhere to federal guidelines.
Modified ‘super-human’ red blood cells containing therapeutic compounds have been developed by researchers as a novel form of drug delivery.
Using embryonic stem cells from frogs, scientists have created living robots; called xenobots, these organisms are able to heal after injury and could be the future of drug delivery.
A study has shown that PBAE nanoparticles could replace viral vectors in gene therapies and provide a safe treatment option for paediatric brain cancer patients.
A proof-of-concept nanorobot design could be used to target cancer cells by their glucose consumption and deliver a drug payload in response to tumour interaction.
The FDA has authorised the first interoperable, automated insulin dosing controller designed to allow more choices for patients looking to customise their diabetes management.
Nanobots have the capacity to precisely release drugs in the body for targeted delivery. Victoria Rees investigates several new developments in the nanobot field, to discover recent advances and how nanobot drug delivery systems may continue to evolve.
Included in this in-depth focus are features on recombinant albumin as a versatile stabiliser and how nanobots will evolve as an effective drug delivery technique.
In this issue are articles that explore the impact of M&As within the life science industry, discuss the security trends for medicinal packaging and investigate genotoxic impurities within pharmaceutical products. Also included are features on nanobot drug delivery systems and Raman as an effective analytical approach.
Development of infrared light-sensitive microcapsules could be the future in targeted drug delivery for cancer treatment, says new research.
University of Leeds researchers have discovered a method to produce polio vaccines made from virus-like particles, which is being trialled on a manufacturing platform.
As the demand for safety-syringes increases, the market for pre-filled safety-engineered devices will increase. This article outlines the main drivers behind this growth.
A pharmaceutical company has announced its intention to create a pressurised Metered Dose Inhaler that will reduce the carbon footprint of the drug delivery system.
A new slow-release formulation and delivery system for the oral contraceptive pill has shown success in pre-clinical trials and could be taken once a month.
RediTrex, a new line of methotrexate products, has been approved by the FDA for the treatment of patients with rheumatoid arthritis.